Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 9/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007576 | 0.83 | KDR (0.51) | NPC1RAB9AKDRACKR3SMN1; SMN2 | |
| SCHEMBL16007186 | 0.82 | KDR (0.54) | NPC1RAB9AKDRSMN1; SMN2TP53 | |
| SCHEMBL16007848 | 0.82 | KDR (0.49) | NPC1RAB9AKDRSMN1; SMN2TP53 | |
| SCHEMBL16007712 | 0.82 | NPC1 (0.43) | NPC1RAB9AKDRACKR3SMN1; SMN2 | |
| SCHEMBL16007458 | 0.81 | NPC1 (0.43) | NPC1RAB9AKDRACKR3SMN1; SMN2 | |
| SCHEMBL16017750 | 0.80 | KDR (0.47) | NPC1RAB9AKDRACKR3SMN1; SMN2 | |
| SCHEMBL16007711 | 0.77 | KDR (0.57) | NPC1RAB9AKDRSMN1; SMN2TP53 | |
| SCHEMBL16007606 | 0.77 | KDR (0.53) | NPC1RAB9AKDRACKR3SMN1; SMN2 | |
| Diethylamine SCHEMBL16007729 | 0.77 | KDR (0.51) | NPC1RAB9AKDRACKR3SMN1; SMN2 | |
| SCHEMBL16007647 | 0.77 | ACKR3 (0.56) | NPC1RAB9AKDRACKR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | VEGFA, EDF1, FLT1 | NPC1 2111/4885RAB9A 743/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.